A Phase II Study of Navarixin (MK-7123) in Combination With Pembrolizumab (MK-3475) in Participants With Selected Advanced/Metastatic Solid Tumors
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 15 Jan 2020
Price : $35 *
At a glance
- Drugs Navarixin (Primary) ; Pembrolizumab (Primary)
- Indications Adenocarcinoma; Colorectal cancer; Non-small cell lung cancer; Prostate cancer; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors Merck Sharp & Dohme
- 11 Jan 2020 Status changed from recruiting to active, no longer recruiting.
- 21 Oct 2019 Planned End Date changed from 8 Jan 2020 to 9 Mar 2020.
- 21 Oct 2019 Planned primary completion date changed from 8 Jan 2020 to 9 Mar 2020.